Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 4, 2015, Pages 578-585

  Ma, G F ^a   Zhang, R F ^a   Ying, K J ^a   Wang, D ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cefoperazone; Cisplatin gemcitabine combination chemotherapy; Defense response

Indexed keywords

CEFOPERAZONE; CISPLATIN; CYTOKINE RECEPTOR; GEMCITABINE; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; INTERLEUKIN 24; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PHARMACOLOGICAL BIOMARKER; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; METHYLATION; NON SMALL CELL LUNG CANCER; PROTEIN PROTEIN INTERACTION; THERAPY EFFECT; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CASE CONTROL STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MICROARRAY ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CISPLATIN; DEOXYCYTIDINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICROARRAY ANALYSIS; NEOADJUVANT THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 84942248049     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. ANGLIM PP, ALONZO TA, LAIRD-OFFRINGA IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008; 7: 81.
2. SPIRO SG, GOULD MK, COLICE GL. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes ACCP evidenced-based clinical practice guidelines. Che st J 2007; 132: 149S-160S.
3. GOLDSTRAW P,BALL D,JETT JR,LE CHEVALIER T,LIM E,NICHOLSON AG,SHEPHERD FA. Non-small-cell lung cancer Lancet 2011 378 1727-1740.
4. LE CHEVALIER T, SCAGLIOTTI G, NATALE R, DANSON S, ROSELL R, STAHEL R, THOMAS P, RUDD R, VANSTEENKISTE J, THATCHER N. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinu m containing regimens in advanced non-smallcell lung cancer: a meta-Analysis of survival outcomes. Lung Cancer 2005; 47: 69-80.
5. ZHAO M, YANG H, GUAN Y, MO M, LIN E, HE J. Effects of ge mcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients with RRM1 low protein expression. Chinese-German J Clin Oncol 2011; 10: 687-691.
6. CRINO L, SCAGLIOTTI G, MARANGOLO M , FIGOLI F, CLERICI M, DE MARINIS F, SALVATI F, CRUCIANI G, DOGLIOTTI L, PUCCI F. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997; 15: 297-303.
7. PLUNKETT W, HUANG P, GANDHI V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995; 6: 7-13.
8. SHERMAN SE, LIPPARD SJ. Structural aspects of plat-inum anticancer drug interactions with DNA. Chem Rev 1987; 87: 1153-1181.
9. SCHILLER JH, HARRINGTON D, BELANI CP, LANGER C, SANDLER A, KROOK J, ZHU J, JOHNSON DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
10. CHEN YC, HSIAO CC, CHEN KD, HUNG YC, WU CY, LIE CH, LIU S-F, SUNG MT, CHEN CJ, WANG TY. Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy. PloS On e 2013; 8: e57053.
11. LI J, SHI R, YU P. Effects of chemotherapy on global gene expression in non-small cell lung cancer. Eur Rev Med Pharmacol Sci 2014; 18: 126-131.
12. GLASAUER A, SENA LA, DIEBOLD LP, MAZAR AP, CHANDEL NS. Targeting SOD1 reduces experimental nonsmall-cell lung cancer. J Clin Invest 2014; 124: 117-128.
13. FAEHLING M, ECKERT R, KAMP T, KUOM S, GRIESE U, STRÄTER J, OTT G, SPENGLER W. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case-contr ol study of overall survival. Lung Cancer 2013; 80: 306-312.
14. BARRETT T, EDGAR R. Gene Expression Omnibus: Microarray Data Storage, Submission, Retrieval, and Analysis. Methods Enzymol 2006; 411: 352-369.
15. GAUTIER L, COPE L, BOLSTAD BM, IRIZARRY RA. affy-Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307-315.
16. SMYTH GK, SPEED T. Normalization of cDNA microarray data. Methods 2003; 31: 265-273.
17. GENTLEMAN R, CAREY VJ, HUBER W, IRIZARRY RA, DUDOIT S. Bioinformatics and computational biology solutions using R and Bioconductor. Vol. 746718470. Springer, 2005.
18. RUSKEY F, WESTON M. Venn diagram survey. Electron J Comb 2005; 5.
19. CONSORTIUM GO. Gene Ontology annotations and resources. Nucleic Acids Res 2013; 41: D530-D535.
20. JIAO X, SHERMAN BT, HUANG DW, STEPHENS R, BASELER MW, LANE HC, LEMPICKI RA. DAVID-WS: a stateful web s ervice to facilitate gene/protein list analysis. Bioinformatics 2012; 28: 1805-1806.
21. FRANCESCHINI A, SZKLARCZYK D, FRANKILD S, KUHN M, SIMONOVIC M, ROTH A, LIN J, MINGUEZ P, BORK P, VON MERING C. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41: D808-D815.
22. KOHL M, WIESE S, WARSCHEID B. Cytoscape: software for visualization and analysis of biological networks, in Data Mining in Proteomics. Springer, 2011; pp. 291-303.
23. LAMB J, CRAWFORD ED, PECK D, MODELL JW, BLAT IC, WROBEL MJ, LERNER J, BRUNET J-P, SUBRAMANIAN A, ROSS KN. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
24. LAMB J. The Connectivity Map: a new tool for biomedical research Nat Rev Cancer 2007 7 54-60.
25. BELINSKY SA, KLINGE DM, DEKKER JD, SMITH MW, BOCKLAGE TJ, GILLILAND FD, CROWELL RE, KARP DD, STIDLEY CA, PICCHI MA. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005; 11: 6505-6511.
26. MASSION PP, ZOU Y, CHEN H, JIANG A, COULSON P, AMOS CI, WU X, WISTUBA I, WEI Q, SHYR Y. Smokingrelated genomic signatures in non-small cell lung cancer. Am J Respir Crit Care Med 2008; 178: 1164-1172.
27. LEE SJ, JEON HS, JANG JS, PARK SH, LEE GY, LEE B-H, KIM CH, KANG YM, LEE WK, KAM S. DNMT3B poly morphisms and risk of primary lung cancer. Carcinogenesis 2005; 26: 403-409.
28. CHANG T-H, SZABO E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-Activated receptor ? in non-small cell lung cancer. Cancer Res 2000; 60: 1129-1138.
29. HUANG CY, FONG YC, LEE CY, CHEN MY, TSAI HC, HSU HC, TANG CH. CCL5 increases lung cancer migration via PI3K, A kt and NF-?B pathways. Biochem Pharmacol 2009; 77: 794-803.
30. HAN JY, CHOI BG, CHOI JY, LEE SY, JU SY. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IG F)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 2006; 54: 227-234.
31. BREN-MATTISON Y, VAN PUTTEN V, CHAN D, WINN R, GERACI MW, NEMENO FF RA. Peroxisome proliferator-Activated receptor-(PPAR?) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2004; 24: 1412-1422.
32. WOENCKHAUS M, MERK J, STOEHR R, SCHAEPER F, GAUMANN A, WIEBE K, HARTMANN A, HOFSTAEDTER F, DIETMAIER W. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 2008; 39: 126-136.
33. TANG Y, SHU G, YUAN X, JING N, SONG J. FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Res 2010; 21: 316-326.
34. TAYLOR CT, KENT BD, CRINION SJ, MCNICHOLAS WT, RYAN S. Human adipocytes are highly sensitive to intermittent hypoxia induced NF-kappaB activity and subsequent inflamma tory gene expression. Biochem Biophys Res Commun 2014; 447: 660-665.
35. SEGER R. Intracellular signaling cascades. Growth Factors 2004; 24: 21-44.
36. STALBERG P , LOPEZ-EGIDO JR, WANG S, GOBL A, BERG K, SKOGSEID B. Differentially expressed cDNAs in PLC?3-induced tumor suppression in a human endocrine pancreatic tumor cell line: activation of the human mismatch repair protein 3 gene. Biochem Bioph ys Res Commun 2001; 281: 227-231.
37. MARTINS M, MCCARTHY A, BAXENDALE R, GUICHARD S, MAGNO L, KESSARIS N, EL-BAHRAWY M, YU P, KATAN M. Tumor suppressor role of phospholipase C? in Ras-triggered cancers. Proc Natl Acad Sci U S A 2014; 111: 4239-4244.
38. FANNING AS, ANDERSON JM. PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane. J Clin Invest 1999; 103: 767-772.
39. MANGI RJ, GRECO T, RYAN J, THORNTON G, ANDRIOLE VT. Cefoperazone versus combination antibiotic therapy of hospital-Acquired pneumonia. Am J Med 1988; 84: 68-74.
40. PHILLI PS S, BRANAMAN-PHILLIPS J. The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-Acquired pneumonia. J Am Geriatr Soc 1993; 41: 1071-1074.
41. BOLIVAR R, FAINSTEIN V, ELTING L, BODEY GP. Cefoperazone for the treatment of infections in patients with cancer. Rev Infect Dis 1983; 5: S181-S187.